LENSAR, Inc. (LNSR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$5.50-5.82%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · LNSR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -51.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 17.7% |
Growth built into the price is above our model estimate.
The price assumes 69.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 29 industry peers
LNSR — CFO transition
Dated 2026-05-29
Interim Chief Financial Officer — Michael A. Rossi: The company appointed an Interim Chief Financial Officer from an external source.
Why it matters: LENSAR placed 10 ALLY systems in Q2, with 13 more awaiting installation. More placements can grow future procedure and service revenue.
Supportive ifQ3 results report more than 10 ALLY placements and a backlog that stays at or above 13 systems.
Worry ifQ3 results report fewer than 10 ALLY placements and a backlog below 13 systems.
Why it matters: Recurring revenue rose 20% in Q2, as procedure revenue and system use grew. Slower growth would weaken this key business trend.
Watch forQ3 recurring revenue grows at least 10% from the year-earlier quarter.
Also watch forQ3 recurring revenue grows less than 10% year over year or declines.
Why it matters: Cash and investments fell from $18.0 million at year-end to $13.6 million in June. A further drop could raise funding pressure.
Worry ifThe Q3 report shows cash, cash equivalents, and investments below $10 million.
Less concerning ifThe Q3 report shows cash, cash equivalents, and investments at or above $13.6 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$189 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $494 loss on $10,000 · 4.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,064 loss on $10,000 · 60.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.